CX-072, an engineered antibody designed for localized therapeutic activity through reliance on tumor-expressing protease(s) to unmask the antigen binding domain targeting PD-L1 in the TME recently reported a favorable safety profile (http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-presents-preliminary-clinical-proof-concept). Here, CD274 is linked to neoplasm.